
Company valuation, historical trends, and peer comparisons.
According to Neurocrine Biosciences, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 16.56B. This represents a change of 13.32% compared to the average of 14.61B of the last 4 quarters.
The mean historical Enterprise Value of Neurocrine Biosciences, Inc. over the last ten years is 9.70B. The current 16.56B Enterprise Value has changed 70.63% with respect to the historical average. Over the past ten years (40 quarters), NBIX's Enterprise Value was at its highest in in the June 2026 quarter at 17.09B. The Enterprise Value was at its lowest in in the December 2016 quarter at 3.26B.
Average
9.70B
Median
9.69B
Minimum
3.27B
Maximum
13.93B
Discovering the peaks and valleys of Neurocrine Biosciences, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 112.52%
Maximum Annual Enterprise Value = 13.93B
Minimum Annual Increase = -30.58%
Minimum Annual Enterprise Value = 3.27B
| Year | Enterprise Value | Change |
|---|---|---|
| 2025 | 13.81B | -0.81% |
| 2024 | 13.93B | 6.72% |
| 2023 | 13.05B | 14.05% |
| 2022 | 11.44B | 40.28% |
| 2021 | 8.16B | -10.84% |
| 2020 | 9.15B | -10.59% |
| 2019 | 10.23B | 44.95% |
| 2018 | 7.06B | 1.69% |
| 2017 | 6.94B | 112.52% |
| 2016 | 3.27B | -30.58% |
The current Enterprise Value of Neurocrine Biosciences, Inc. (NBIX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
13.60B
5-year avg
12.08B
10-year avg
9.70B
Neurocrine Biosciences, Inc.’s Enterprise Value is greater than Supernus, Inc. (1.84B), less than Jazz Pharmaceuticals plc (18.67B), greater than Vanda Pharmaceuticals Inc. (194.66M), greater than Axsome Therapeutics, Inc. (7.11B), greater than Acadia Pharmaceuticals Inc. (2.78B), greater than Rapport Therapeutics, Inc. Common Stock (1.18B), less than H. Lundbeck A/S (50.61B), greater than Biohaven Ltd. (2.51B), greater than Neumora Therapeutics, Inc. Common Stock (-10144921.00), greater than GH Research PLC (1.02B),
| Company | Enterprise Value | Market cap |
|---|---|---|
| 1.84B | $1.64B | |
| 18.67B | $15.06B | |
| 194.66M | $234.62M | |
| 7.11B | $7.21B | |
| 2.78B | $3.70B | |
| 1.18B | $1.24B | |
| 50.61B | $5.63B | |
| 2.51B | $2.30B | |
| -10144921.00 | $106.35M | |
| 1.02B | $1.37B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Neurocrine Biosciences, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Neurocrine Biosciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Neurocrine Biosciences, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Neurocrine Biosciences, Inc. (NBIX)?
What is the 3-year average Enterprise Value for Neurocrine Biosciences, Inc. (NBIX)?
What is the 5-year average Enterprise Value for Neurocrine Biosciences, Inc. (NBIX)?
How does the current Enterprise Value for Neurocrine Biosciences, Inc. (NBIX) compare to its historical average?